Evidence map›Paper›PMID 34248160›Full record

ArticleThe Canadian journal of hospital pharmacy2021

Comparison of Clinical Importance of Drug Interactions Identified by Hospital Pharmacists and a Local Clinical Decision Support System.

Louise Lau, Harkaryn Bagri, Michael Legal, Karen Dahri

Open access · bronzeAbstract read
In one paragraph

Article in The Canadian journal of hospital pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. TLC-Act: A Novel Tool for Managing Drug Interactions.The Canadian journal of hospital pharmacy · 2022
    Article
  5. Community pharmacist perceptions of drug-drug interactions.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Louise Lau, BSc, BSc Pharm, ACPR, is a Clinical Pharmacist with Vancouver General Hospital, Vancouver, British Columbia.
Harkaryn Bagri, BSc, BScPharm, ACPR, is a Clinical Pharmacist with Surrey Memorial Hospital, Surrey, British Columbia.
Michael Legal, BScPharm, PharmD, ACPR, FCSHP, is a Clinical Manager with Lower Mainland Pharmacy Services, Vancouver, British Columbia.
Karen Dahri, BSc, BScPharm, PharmD, ACPR, FCSHP, is a Clinical Pharmacotherapeutic Specialist (Internal Medicine) with Vancouver General Hospital and an Assistant Professor (Partner) with the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.
Vancouver General Hospital · CASurrey Memorial Hospital · CAWest Pharmaceutical Services (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-drug interactions (DDIs) may cause adverse drug events, potentially leading to hospital admission. Clinical decision support systems (CDSSs) can improve decision-making by clinicians as well as drug safety. However, previous research has suggested that pharmacists are concerned about discrepancies between CDSSs and common clinical practice in terms of severity ratings and recommended actions for DDIs.

objectivesThe primary objective was to characterize the level of agreement in terms of DDI severity ranking and actions recommended between the local CDSS and pharmacists. The secondary objectives were to determine the level of agreement among pharmacists concerning DDI severity, to determine the influence of the CDSS on clinicians' decision-making, and to review the literature supporting the severity rankings of DDIs identified in the study institution's database.

methodsThis 2-part survey study involved pharmacists and pharmacy residents working at 1 of 4 health organizations within the Lower Mainland Pharmacy Services, British Columbia, who were invited to participate by email. Participants were first asked to rank the severity of 15 drug pairs (representing potential DDIs) on a 5-point Likert scale and to select an action to manage each interaction. Participants were then given the CDSS severity classification for the same 15 pairs and again asked to select an appropriate management action.

resultsOf the estimated 500 eligible pharmacists, a total of 73 pharmacists participated, for a response rate of about 15%. For DDIs of moderate severity, most participants chose to monitor. For severe and contraindicated interactions, the severity ranking and action proposed by participants varied, despite the same severity classification by the CDSS. There was poor agreement among respondents about the severity of the various DDIs. Moreover, knowledge of the CDSS severity ranking did not seem to change the actions proposed by most respondents.

conclusionThis study identified a gap between the local CDSS and clinical practice. There were discrepancies in terms of severity rankings and actions proposed to manage DDIs, particularly for severe and contraindicated DDIs. The current CDSS did not appear to have a large impact on clinical decision-making, which suggests that it may not be functioning to its full potential.

Indexed as

clinical decision support systemdrug-drug interactions

Identifiers

PMID34248160
PMCPMC8237957
OpenAlexW3183015354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.